Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
SGLT2 inhibitors improve atrial conduction time in diabetes
Última actualización 29 de agosto de 2026
Key finding
BMI decreased from 30.9 to 29.7 kg/m² (p < 0.001)
This study evaluated the effects of sodium-glucose cotransporter 2 inhibitors on atrial conduction time in type 2 diabetes patients and found significant improvements.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of sodium-glucose cotransporter 2 inhibitors on atrial conduction time in type 2 diabetes patients and found significant improvements.
Clinical relevance
These findings highlight the potential of SGLT2 inhibitors not only in managing diabetes but also in improving heart health. Given the high prevalence of cardiovascular disease among diabetes patients, these results could inform treatment strategies and enhance patient outcomes.
Keep in mind
Study design may limit generalizability to broader populations. Sample size and demographic characteristics were not specified. Potential confounding factors were not fully addressed.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Ercan T, Fethullah K, Songül B, Attila N. Sodium-glucose cotransporter 2 inhibitors improve total atrial conduction time in patients with type 2 diabetes. Reviews in Cardiovascular Medicine. 2026;27(5):50764. doi:10.31083/RCM50764
Efectos Principales
Total Atrial Conduction Time (TACT) decreased significantly (p < 0.001).
Body Mass Index (BMI) decreased from 30.9 to 29.7 kg/m² (p < 0.001).
Glycated Hemoglobin (HbA1c) decreased from 8.3% to 7.1% (p < 0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to SGLT2 inhibitors and BMI, Diastolic blood pressure, HbA1c, and 6 more.
This study contributes evidence to
Primary intervention
SGLT2 inhibitors
Primary outcomes
- BMI
- Diastolic blood pressure
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
9
Evidence pairs
9
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
4
Related topics
9
Evidence pairs
1034
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 9 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
SGLT2 Inhibitors and HbA1c
Evidencia relacionada
Relación de evidencia
SGLT2 Inhibitors and Body Mass Index
Guardar evidencia
Relación de evidencia
SGLT2 Inhibitors and Adipokine and Angiogenic Markers
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Diastolic blood pressure
SGLT2 inhibitors → Diastolic blood pressure
SGLT2 inhibitors → Diastolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerSystolic blood pressure
SGLT2 inhibitors → Systolic blood pressure
SGLT2 inhibitors → Systolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerTotal Atrial Conduction Time (TACT)
SGLT2 inhibitors → Total Atrial Conduction Time (TACT)
SGLT2 inhibitors → Total Atrial Conduction Time (TACT)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- BMI decreased by 1.2 kg/m² (p < 0.001).
- HbA1c levels reduced by 1.2% (p < 0.001).
- Total cholesterol decreased by 9 mg/dL (p = 0.011).
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Patients at risk for cardiovascular disease.
Tener en Cuenta
- Results may not apply to non-diabetic populations.
- Long-term effects of SGLT2 inhibitors were not assessed.
- Further studies are needed to confirm findings in diverse populations.
Entre Líneas
- Study design may limit generalizability to broader populations.
- Sample size and demographic characteristics were not specified.
- Potential confounding factors were not fully addressed.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Body Mass Index.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
View evidenceMedications
SGLT2 Inhibitors → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 2 estudios
View evidenceMedications
SGLT2 Inhibitors → Blood Pressure
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
3 studies
outcome_hubMeasures HbA1c as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
3 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
2 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
2 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on SGLT2 inhibitors and HbA1c
Intervention: SGLT2 inhibitorsOutcome: HbA1c
3 results
All studies on SGLT2 inhibitors and BMI
Intervention: SGLT2 inhibitorsOutcome: BMI
2 results
All studies on SGLT2 inhibitors
Intervention: SGLT2 inhibitors
3 results
All studies measuring HbA1c
Outcome: HbA1c
3 results
All studies measuring BMI
Outcome: BMI
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve HbA1c?
Strong Evidence
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 78.5 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 22 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors affect body mass index?
Strong Evidence
SGLT2 Inhibitors appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve adipokine and angiogenic markers?
Strong Evidence
SGLT2 Inhibitors appears to improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Total cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Triglycerides
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve blood pressure?
Strong Evidence
SGLT2 Inhibitors may improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Systolic blood pressure
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
- 2
Diastolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
SGLT2 inhibitors improve quality of life in Type 2 diabetesTofogliflozin improves weight loss in type 2 diabetes patients with obesityHigh-protein diet may reduce cardiometabolic risks in diabetes patientsVideo education improves dietary compliance for diabetesHibiscus extract may improve kidney function in type 2 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.